$NKTR

Rezpegaldesleukin, an IL-2 receptor agonist, showed early upregulation of Treg markers and suppression of inflammatory axes in a phase 2b trial for atopic dermatitis. Emma Guttman-Yassky, MD, noted significant biomarker changes by week 2, predicting week 16 responses. Nektar Therapeutics disclosed relevant findings, with mean EASI scores falling 64.3% by week 16. Data not yet peer-reviewed.

Nektar Therapeutics (NKTR) will release its Q3 2026 financial results on November 12, 2026, after U.S. market close. A conference call will follow, led by CEO Howard Robin. The company is a biotech firm focused on autoimmune and inflammatory disease treatments, with lead candidate rezpegaldesleukin in clinical trials.

Analysts updated ratings for Nektar Therapeutics (NKTR), Roche Holding AG (RHHVF), and Henry Schein (HSIC). UBS gave NKTR a Hold rating with a $53 target; consensus is $132.70. Jefferies maintained a Sell on RHHVF with a CHF250 target; consensus is $444.60. Leerink Partners kept a Hold on HSIC with a $89 target; consensus is $101.23.

Leerink Partners selected Nektar Therapeutics (NKTR), Protagonist Therapeutics (PTGX), and Shattuck Labs (STTK) as top picks in emerging immunology. The firm highlighted NKTR's phase 3 asset rezpegaldesleukin for atopic dermatitis. PTGX and STTK were also noted for their potential.

Nektar Therapeutics (NKTR) presented new clinical data for rezpegaldesleukin at the 2026 EADV Congress, showing long-term outcomes in atopic dermatitis and alopecia areata. Despite this, NKTR's stock has declined 41% in 1 month and 39% in 3 months, though it has a 3-year total shareholder return. Analysts suggest NKTR could be 71% undervalued at $144.40 per share, with a robust cash position extending its runway into 2027.

UBS initiated coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and a $53 price target, citing catalyst timing and competitive concerns. The stock has fallen 47% over six months. UBS noted Nektar's leadership in regulatory T cell space and positive Phase 2b data for rezpegaldesleukin. The company reported a smaller-than-expected Q2 loss but missed revenue expectations. Nektar was awarded $90M in damages against Eli Lilly.

BTIG maintained a Buy rating on Nektar Therapeutics with a $178 price target, implying a 336.3% upside from the Oct 8 close of $40.80. The firm cited positive legal outcomes and strong market research for REZPEG as key reasons. Recent analyst price targets for NKTR range from $50 to $185.

Raymond James initiated coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Market Perform rating, citing its focus on autoimmune therapies and cash burn. The stock is down 46% over six months, with a market cap of $1.39 billion. Nektar reported a smaller-than-expected Q2 2026 loss but missed revenue forecasts. The company won a $90 million verdict against Eli Lilly and received a Buy rating with a $185 price target from H.C. Wainwright.

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

Nektar Therapeutics (NKTR) won a $115 million lawsuit against Eli Lilly (LLY), resolving a multi-year overhang. The verdict, including interest, amounts to ~5% of NKTR's market cap. Despite the win, NKTR's stock fell over $200 million in market cap due to market volatility and rising yields. Cedar Grove Capital Management views this as a net positive for NKTR, removing a long-standing uncertainty.